Novo Holdings-backed Rezera files for Nasdaq IPO under ticker RZRA

Clinical-stage biotech Rezera, developing oral NLRP3 inhibitors for cardiovascular and neurologic disease, has filed for a Nasdaq IPO to list under ticker RZRA. Jefferies, TD Cowen and Cantor are joint bookrunners; Novo Holdings owns 24.42%.

Detected & updated continuously · Source: Nebula